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Title: Combining information on C reactive protein and serum albumin into the Glasgow 
Prognostic Score strongly discriminates survival of myelofibrosis patients 
 
To the Editor: 
Primary- (PMF) and secondary-myelofibrosis (SMF) are Philadelphia-chromosome-negative 
myeloproliferative-neoplasms characterized by strong myeloproliferation and profound 
inflammatory atmosphere. Myelofibrosis patients often face a significant weight loss and 
cachexia during disease course. Both elevated C-reactive-protein (CRP) [1, 2] and low albumin 
[3] were associated with advanced disease features and adverse outcomes in patients with 
myelofibrosis. The Glasgow Prognostic Score (GPS) [4], developed in patients with non-small-
cell lung cancer, integrates information on CRP and albumin. It was associated with poor 
nutritional and performance status, higher comorbidity and worse prognosis in various cohorts 
of patients with different malignancies [4, 5]. Clinical and prognostic properties of the GPS 
were not previously described in the context of myelofibrosis. Therefore, we aimed to 
investigate prognostic properties of CRP, albumin and the GPS in patients with myelofibrosis 
and to assess the relationship of the GPS with disease specific features. 
 
We retrospectively analyzed 88 patients with myelofibrosis (67 PMF, 21 SMF) that were 
evaluated in our institution in period from 2004 to 2018. All patients provided written informed 
consent for molecular analyses. The study was approved by the Institutional Review Board. 
Diagnoses were established by the 2016 WHO and the IWG-MRT criteria. Disease specific 
clinical and hematological parameters were recorded (age, gender, white-blood-cells [WBC], 
differential-blood-count, circulatory-blasts, hemoglobin, mean-corpuscular-volume [MCV], 
red-cell-distribution-width [RDW], platelets, mean-platelet-volume [MPV], CRP, lactate-
dehydrogenase [LDH], albumin, serum-iron, total-iron-binding-capacity, transferrin-
saturation, ferritin, transfusion-dependency, presence of constitutional-symptoms, degree of 
bone-marrow-fibrosis, blast-phase disease, spleen and liver size, JAK2, CALR and MPL 
mutational status). For molecular analyses, DNA was isolated from full blood by QIAamp 
DNA Blood Mini Kit (Qiagen, ID 51104). JAK2-V617F was assessed by allele-specific PCR, 
CALR1 and MPL exon 10 mutations were screened by high–resolution-melting dye assays and 
any sample sequence that deviated from normal was Sanger-sequenced. Patients were divided 
into the GPS risk groups according to the originally proposed method: patients with both 
CRP>10 mg/L and albumin<35 g/L were given 2 points (poor-risk), patients with only CRP>10 
mg/L or albumin<35 g/L were given 1 point (intermediate-risk), whereas patients with both 
CRP≤10 mg/L and albumin≥35 g/L were given 0 points (good-risk).  
Normality of data distribution was tested using the Shapiro Wilk test. Variables were compared 
between groups using the Mann-Whitney-U test and the χ2 (Chi-squared) test. Trends of rise 
or fall in disease specific parameters over the GPS risk groups were tested using the Spearman 
rank correlation for numerical and the χ2 test for trend for categorical variables. The Cox-
Mantel version of the log-rank test and the Cox-regression-analysis were used to compare 
survival between groups. Initial survival associations were recognized using the custom made 
MS Excel workbook [6]. P values <0.05 were considered statistically-significant. Statistical 
analyses were performed using the MedCalc-Statistical-Software version 18.2.1 (MedCalc 
Software BVBA, Ostend, Belgium). 
 
Mean age in our cohort was 66.3±11 years, 51/88 (58%) patients were males. A total of 55/88 
(62.5%), 28/88 (31.8%) and 5/88 (5.7%) patients were classified as good risk (0 points), 
intermediate risk (1 point) and poor risk (2 points) according to the GPS, respectively. PMF 
and SMF patients did not significantly differ in CRP (median 4.5 vs 3 mg/L; P=0.759) nor 
albumin (median 43 vs 43 g/L; P=0.517) and were equally distributed among the GPS risk 
groups (P=0.969). Patients classified into the GPS groups of higher risk expectedly had higher 
CRP (P<0.001) and lower albumin (P<0.001), but also more frequently had presence of 
constitutional-symptoms (P=0.004), massive-splenomegaly (P=0.056), blast-phase-disease 
(P=0.001), presence of circulatory-blasts (P=0.008), higher absolute-monocyte-count 
(P=0.029), lower hemoglobin (P<0.001), lower platelets (P=0.026), higher LDH (P=0.006), 
higher RDW (P=0.011), higher ferritin (P<0.001), and more frequently were transfusion-
dependent (P<0.001). They were also more likely to belong to the higher Dynamic-
International-Prognostic-Scoring-System (DIPSS) risk category (P<0.001). We detected no 
statistically significant associations of the GPS with JAK2 (P=0.931), CALR (P=0.651), MPL 
(P=0.859) mutational status, degree of bone-marrow-fibrosis (P=0.210), nor with other 
measured variables (P>0.05 for other comparisons).   
As shown in a Figure1a and 1b, both CRP>10 mg/L [hazard-ratio (HR)=3.42; P<0.001] and 
albumin<35 g/L (HR=4.68; P<0.001) were univariately associated with inferior survival. These 
associations remained statistically significant in the multivariate model including CRP>10 
mg/L (HR=2.49; P=0.013), albumin<35 g/L (HR=2.74; P=0.031) and the DIPSS (HR=2.31; 
P<0.001). Accordingly, the GPS was able to well distinguish patients with different prognosis 
as shown in a Figure 1c (overall P<0.001; P<0.001 for all three comparisons between survival 
curves). The GPS remained statistically significant predictor of inferior survival in the 
multivariate model including the GPS [intermediate risk GPS (HR=2.08; P=0.040), poor risk 
GPS (HR=23.52; P<0.001)], the DIPSS (HR=2.72; P<0.001), age (HR=1.02; P=0.298) and 
male gender (HR=0.77; P=0.443). We further analyzed how the GPS performs after controlling 
for the individual DIPSS-included factors and observed that the GPS and all factors besides 
hemoglobin <100 g/L retained statistical significance: GPS (HR=2.68; P=0.004), age>65 
years (HR=2.05; P=0.045), WBC>25 x109/L (HR=2.7; P=0.014), hemoglobin<100 g/L
 (HR=0.99; P=0.979), constitutional-symptoms (HR=2.33; P=0.016), circulatory-
blasts≥1% (HR=2.38; P=0.013).  
 
Our study identifies the GPS as a strong predictor of inferior survival in myelofibrosis, 
encompassing valuable prognostic information of metabolic parameters not covered within the 
DIPSS prognostic system. Patients classified into higher GPS risk groups present with a variety 
of negative prognostic features representing stronger myeloproliferation, more aggressive 
disease biology, higher inflammatory status and tendency for iron overload. JAK inhibitors, 
that are a standard of care for DIPSS intermediate-2- and high-risk patients, can improve 
inflammatory and nutritional parameters in a subset of treated patients [7] and thus have 
theoretical potential to reverse negative prognostic impact of the higher GPS. However, 
patients with higher GPS are also less likely to respond to JAK inhibitors as they pool 
characteristics predictive on non-response to therapy (lower hemoglobin, lower platelets, larger 
spleen size [8]). Future studies on larger prospective cohorts of patients are needed to further 
define the role of the GPS in prognostication of patients with myelofibrosis, especially from 
the point of view of new and emerging cachexia modulatory drugs. 
In conclusion, myelofibrosis patients with higher GPS present with features of more advanced 
disease. The GPS possesses strong DIPSS-independent prognostic properties and might help 
in recognition of patients under increased risk of death.    
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Figure 1 Overall survival stratified by a) C reactive protein (CRP), b) albumin and c) the 
Glasgow prognostic score (GPS) risk groups. 
 
